Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Farhad Ravandi, MBBS, Christopher Pocock, MBBS, Dominik Selleslag, MD, Pau Montesinos, MD PhD, Hamid Sayar, MD MSc, Maurizio Musso, MD, Angela Figuera Alvarez, Hana Safah, MD, William Tse, MD FACP, Sang Kyun Sohn, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Timothy Chevassut, Francesca Pierdomenico, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Hervé Dombret, MD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-137669

Published: 2020

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

Journal Articles

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Jae-Ho Yoon, MD PhD, Seok Lee, MD PhD, Dae Sik Kim, MD PhD, Se Ryun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Soo-Mee Bang, MD PhD, Youngil Koh, MD, Ho-Young Yhim, MD, Sang Kyun Sohn, MDPhD, Ik-Chan Song, MD, Hong-ghi Lee, MD PhD, June-Won Cheong, MDPhD, Yunsuk Choi, MD, Ho-Jin Shin, MD PhD

Blood (2017) 130 (Supplement 1): 5004.

https://doi.org/10.1182/blood.V130.Suppl_1.5004.5004

Published: 2017

Journal Articles

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Blood (2017) 130 (Supplement 1): 5075.

https://doi.org/10.1182/blood.V130.Suppl_1.5075.5075

Published: 2017

Journal Articles

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeoung Kim, Seung-Shin Lee, MD, Seo-Yeon Ahn, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD, Sang Kyun Sohn, MDPhD, Yoo Hong Min, MD PhD, June-Won Cheong, MDPhD, Hyeoung-Joon Kim, Zhaolei Zhang, PhD, Dennis (Dong-Hwong) Kim, MD PhD

Blood (2017) 130 (Supplement 1): 3955.

https://doi.org/10.1182/blood.V130.Suppl_1.3955.3955

Published: 2017

NARROW

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Email alerts

ASH Publications

American Society of Hematology

Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Maintenance Trial

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Blinatumomab Treatment in Korean Adult Patients with Relapse/Refractory Acute Lymphoblastic Leukemia

Morphological Subtype According to the FAB Classification Correlates with Molecular Subtype Using Genomic Risk Classification Based on Somatic Mutation Profiles in Normal Karyotype AML

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only